Hamlet BioPharma (7ZT) Stock Overview
Engages in the development of drugs for the treatment and prevention of cancer in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
7ZT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Hamlet BioPharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.83 |
| 52 Week High | €0.83 |
| 52 Week Low | €0.33 |
| Beta | 0.32 |
| 1 Month Change | 40.75% |
| 3 Month Change | 65.14% |
| 1 Year Change | n/a |
| 3 Year Change | 215.21% |
| 5 Year Change | n/a |
| Change since IPO | 7.94% |
Recent News & Updates
Is Hamlet BioPharma (FRA:7ZT) In A Good Position To Invest In Growth?
Jan 03
Here's Why We're Watching Hamlet BioPharma's (FRA:7ZT) Cash Burn Situation
Jul 30Shareholder Returns
| 7ZT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.7% | 1.5% | 2.9% |
| 1Y | n/a | 4.6% | 12.1% |
Return vs Industry: Insufficient data to determine how 7ZT performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 7ZT performed against the German Market.
Price Volatility
| 7ZT volatility | |
|---|---|
| 7ZT Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 7ZT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7ZT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 7 | Catharina Svanborg | hamletbiopharma.com |
Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company’s products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer.
Hamlet BioPharma AB (publ) Fundamentals Summary
| 7ZT fundamental statistics | |
|---|---|
| Market cap | €1.62b |
| Earnings (TTM) | -€5.29m |
| Revenue (TTM) | €19.12k |
Is 7ZT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7ZT income statement (TTM) | |
|---|---|
| Revenue | SEK 208.04k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 208.04k |
| Other Expenses | SEK 57.80m |
| Earnings | -SEK 57.59m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 22, 2026
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 100.00% |
| Net Profit Margin | -27,682.39% |
| Debt/Equity Ratio | 0% |
How did 7ZT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 02:38 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hamlet BioPharma AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.